Cross-source identity
National Provider Identifier 1295814408 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1295814408 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1295814408 | 96 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1295814408 | 140 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 8ddccae3… | Canonical resolved node · 4 identifier(s) · 7 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,938 | 96 |
| Manufacturer | Amount | Records |
|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $383 | 12 |
| Phathom Pharmaceuticals, Inc. | $366 | 7 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $283 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ozempic(Semaglutide) | 244 | $293,359 |
| Jardiance(Empagliflozin) | 125 | $165,616 |
| Eliquis(Apixaban) | 56 | $77,902 |
| Mounjaro(Tirzepatide) | 67 | $77,384 |
| Entresto(Sacubitril/Valsartan) | 52 | $57,737 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Phadia Us Inc. (MI) | cms_open_payments |
| ← pays | Verity Pharmaceuticals Inc. (NJ) | cms_open_payments |
| ← pays | Ascensia Diabetes Care Us Inc. (NJ) | cms_open_payments |
| ← pays | Radius Health, Inc. (MA) | cms_open_payments |
| ← pays | Novo Nordisk Inc (NJ) | cms_open_payments |
| ← pays | Astrazeneca Pharmaceuticals Lp (DE) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| 8 |
| Lilly Usa, Llc | $280 | 7 |
| Merck Sharp & Dohme Llc | $217 | 9 |